

# ALTSuLIN® ADVANCED THERAPY ON TRACK TO ERADICATE TYPE 1 DIABETES IN MILLIONS

*Biotech ALTuCELL Seeks Partners for Clinical Trials*

DIX HILLS, NEW YORK, USA,  
December 10, 2014 /EINPresswire.com/  
-- [Type 1 diabetes](#) affects approximately



three million people in the United States. Each year 15,000 children are diagnosed with type 1 diabetes, one of the most frequent chronic childhood diseases.

ALTuCELL, a pre-clinical cellular engineering and biotech company specializing in the treatment of diabetes mellitus, type 1 and insulin-dependent type II, is seeking FDA approval of its registered ALTSuLIN® product, a pre-clinical pathway targeting type 1 diabetes.

“

Our mission is to cure, not treat, type 1 diabetes. We need partners to help bring ALTSuLIN® to the next level.

*Gary Harlem*

“Our mission is to cure, not treat, type 1 diabetes through scientific therapy that I would use on my own child,” said Gary Harlem, founder and CEO of ALTuCELL.

ALTuCELL has reached a critical stage in its search for a potential cure for type 1 diabetes. As the Company and its chief science officer Riccardo Calafiore M.D., move to complete primate studies, there is a need for additional working capital.

“We have committed significant resources to advance the science of our two patents to this stage,” says Harlem. “We need partners to help bring ALTSuLIN® to the next level.”

ALTuCELL’s patented encapsulation treatment delivers a non-invasive approach to cell transplantation without requiring immunosuppressant therapy. By transplanting porcine-derived Sertoli cells, ALTuCELL has successfully demonstrated in animal trials the ability to drastically reduce or eliminate the need for insulin injections.

The science of transplanting porcine derived islet cells into humans is not new and has advanced significantly over the past decade. ALTuCELL’s development plan is to apply ALTSuLIN®’s patented platform technologies on ultra-purification of alginates and micro encapsulation for islet cell xenotransplantation of Sertoli cells from pigs to humans. Dr. Calafiore’s highly skilled team’s significant breakthrough has created a fast-track opportunity to demonstrate this unique protocol’s viability in humans.

Type 1 (or insulin-dependent) diabetes is an autoimmune disease that results in the permanent destruction of beta cells, the insulin-secreting cells in the pancreas. This lack of insulin results in elevated blood sugar (hyperglycemia).

Insulin replacement therapy is currently the only approved therapy for type 1 diabetes, but the blood sugar control needed for the prevention of diabetes complications (e.g., retinopathy, neuropathy, cardiovascular disease and neuropathy) cannot be maintained through insulin replacement alone. As a result, the healthcare costs associated with type 1 diabetes in the U.S. each year is approximately \$14.9 billion.

Lou Ceparano  
Close-Up TV News  
(631) 421-8500  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.